Estats Units - anglès - NLM (National Library of Medicine)

carilion materials management - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - atomoxetine 10 mg - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) . [see clinical studies ( )] 14 a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of

Malàisia - anglès - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - atomoxetine hydrochloride -

Israel - anglès - Ministry of Health

eli lilly israel ltd, israel - atomoxetine as hydrochloride - hard capsule - atomoxetine as hydrochloride 10 mg - atomoxetine - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. treatment must be initiated by a specialist in the treatment of adhd, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. diagnosis should be made according to current dsm criteria or the guidelines in icd.in adults, the presence of symptoms of adhd that were pre-existing in childhood should be confirmed. third-party corroboration is desirable and strattera should not be initiated when the verification of childhood adhd symptoms is uncertain. diagnosis cannot be made solely on the presence of one or more symptoms of adhd. based on clinical judgment, patients should have adhd of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’

Malta - anglès - Medicines Authority

eli lilly & co. limited - atomoxetine - hard capsule - atomoxetine 10 mg - psychoanaleptics

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

eli lilly nederland b.v. - atomoxetine hydrochloride - capsule, hard - 10 milligram(s) - centrally acting sympathomimetics; atomoxetine

Emirats Àrabs Units - anglès - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

pharmatrade spain - 28's (7's blister x 4) - capsule - 10mg / capsule - central nervous system-psychoses , related disorders

Canadà - anglès - Health Canada

eli lilly canada inc - atomoxetine (atomoxetine hydrochloride) - capsule - 10mg - atomoxetine (atomoxetine hydrochloride) 10mg - miscellaneous central nervous system agents

Estats Units - anglès - NLM (National Library of Medicine)

carilion materials management - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - atomoxetine 25 mg - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) . [see clinical studies ( )] 14 a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of

Estats Units - anglès - NLM (National Library of Medicine)

tya pharmaceuticals - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - atomoxetine 25 mg - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) . [see clinical studies ( )] 14 a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of

Estats Units - anglès - NLM (National Library of Medicine)

carilion materials management - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) . [see clinical studies ( )] 14 a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of